VEGF as a Therapeutic Target in Cancer

By N. Ferrara. Oncology, 2005

604 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy (2012, background): “Rituximab (Rituxan®) for non-Hodgkin’s lymphoma treatment [48], Trastuzumab (Herceptin®) for breast cancer treatment [49], Bevacizumab (Avastin®) designed to inhibit angiogenesis [50], and Cetuximab (Erbitux®) for advanced colorectal cancer treatment [51] have been developed and approved by FDA for ”
Nanocarriers as an emerging platform for cancer therapy. (2007, background): “The first angiogenesis inhibitor for treating colorectal cancer, Bevacizumab (Avastin), an anti-VEGF mAb that inhibits the factor responsible for the growth of new blood vessels, was approved in 200”
Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. (2014, background): “angiogenesis strategy in both animal models and cancer patients [216].”